The Defense Department yanked mandatory testosterone screening rules for service members less than 24 hours after posting them, a stumble that hands critics an easy shot at an initiative designed to sharpen military readiness.
The Defense Health Agency published its "Clinical Guidance for Health and Human Performance Optimization" on Wednesday, September 2, laying out screening protocols that would have required testosterone blood tests for every male service member age 30 and older during annual health assessments. By Thursday the page on the DHA website returned a notice saying the content had been "moved or been removed," and a Pentagon official confirmed to The Hill that the guidance had been temporarily rescinded to allow for "updates."
The abrupt reversal leaves an interim policy on testosterone deficiency screenings in place while the department drafts a final version it says will arrive "shortly." What those updates involve, and why the guidance needed them after it had already been cleared for publication, remain unanswered.
Defense Secretary Pete Hegseth first announced the testosterone screening effort in July, casting it as a readiness measure aimed at keeping troops at peak operational capacity. He framed the program not as artificial enhancement but as a duty owed to the men and women who serve.
"While we invest heavily in our weapon systems, platforms and gear, our most decisive tactical advantage will always be the individual warfighter. We have a sacred duty to maintain that advantage, which is why we must constantly look for new ways to optimize your performance, your resilience and your long-term health."
Hegseth also described the effort in terms of biological readiness. A Pentagon official echoed that language in a separate statement, as Just The News reported: "It's not about artificial enhancement. It's about restoring and optimizing your natural capabilities, protecting your longevity and ensuring you have the biological foundation required to sustain the fight."
The underlying logic is straightforward. Low testosterone can sap energy, reduce muscle mass, impair recovery, and degrade the physical edge combat troops need. Catching deficiencies early and offering treatment, including testosterone replacement therapy, fits squarely within the military's interest in fielding the most capable force possible.
The clinical guidance, designated DHA-IPM-26-007, drew separate screening pathways for men and women. Men 30 and older would have received mandatory testosterone blood tests as part of their annual health assessments. Men under 30 would only be tested if a health professional flagged a concern or if the service member requested it. Those diagnosed with low testosterone would receive treatment options, including hormone therapy, though Newsmax noted that participation in therapy would not be compulsory.
Female service members faced a different protocol. They would be asked about disrupted menstrual cycles that could signal hormonal dysregulation. The withdrawn guidance also included recommendations for screening women for hormonal imbalances related to menopause and perimenopause, with testosterone therapy reserved for specific diagnoses such as Hypoactive Sexual Desire Disorder, the Washington Examiner reported.
The scope was broad. Every branch, active-duty and reserve, would have been affected. And the guidance was intended to take effect immediately upon publication, which makes the next-day pullback all the more conspicuous.
The timeline is tight and unflattering. Wednesday: the DHA posts the clinical guidance on its website. Thursday: the page goes dark, Breitbart confirmed, returning a "PAGE NOT FOUND" error. A Pentagon official then tells reporters the document was pulled for updates, without specifying what needed fixing.
That official offered a statement reaffirming the department's commitment to the program's goals:
"The Department remains committed to addressing hormone deficiencies, protecting the long-term health of its Service members and enabling peak operational performance."
The reassurance is welcome, but it raises an obvious question: if the department is committed and the interim guidance remains in place, what went wrong with the version published Wednesday? A guidance document that survives less than 24 hours suggests either a drafting error, a review process that failed to catch problems before publication, or internal disagreement that surfaced too late.
Derek Griffith, who directs the program for research on men's health at the University of Pennsylvania, had previously told The Hill that Hegseth's rationale for the screening program is not backed by science. Griffith pointed out that only about 2 percent of the male population has low testosterone, a figure he said does not "suggest that this is a major problem" in the U.S. military.
But Griffith also acknowledged that testosterone replacement therapy can aid the health of men who genuinely suffer from low levels. The dispute, then, is less about whether low testosterone is real and treatable than about whether mandatory screening across the entire force is a proportionate response to a condition affecting a small fraction of service members.
That is a fair debate to have. And it is a debate the Pentagon made harder to win by fumbling the rollout. When you announce a program with the stated goal of keeping troops on the "leading edge of lethality," publishing guidance that has to be pulled within hours does not project the operational competence you are selling.
For now, the interim guidance on testosterone deficiency screenings remains in effect. Service members who want to be tested can still pursue it through existing channels. The mandatory component for men over 30, the centerpiece of the clinical guidance, is in limbo until the revised version appears.
Several questions remain open. No one has explained what specific content required updating. No timeline more precise than "shortly" has been offered for the final guidance. And it is unclear whether the female screening provisions will survive the revision unchanged or face their own rework.
The underlying initiative still makes sense on its own terms. Military readiness depends on physical performance, and hormone health is part of that equation. Hegseth identified a real gap in how the military monitors the biological fitness of its personnel, and addressing it is a reasonable policy goal that most service members and their families would welcome.
But good policy poorly executed gives opponents a free win. The Pentagon did not need to hand critics a one-day publication-to-rescission cycle that makes a serious health initiative look half-baked. If the department wants to project strength and precision, it should start by making sure its own paperwork is ready before it goes live.
A military that asks its troops to be combat-ready on day one ought to hold its own bureaucracy to the same standard.
